Danish Genmab inks $1.1 bn deal with Johnson & Johnson

Danish pharmaceutical group Genmab said Thursday it had reached a deal worth up to $1.1 billion (876 million euros) with US drug giant Johnson & Johnson for the rights to the cancer treatment Daratumumab.

The deal with J&J unit Janssen Biotech involves a $55 million upfront payment to Genmab and an investment of about $80 million in new Genmab shares, the Danish company said.

"Genmab could also be entitled to up to $1 billion in development, regulatory and sales milestones, in addition to tiered double digit royalties," it added.

Daratumumab is used to treat multiple myeloma, a type of bone marrow cancer, and might have potential for other cancers such as acute myeloid leukemia.

Under the terms of the agreement, Genmab will grant Janssen an exclusive worldwide license to develop and commercialise Daratumumab.

"Daratumumab is an exciting, innovative compound, and we are delighted to add it to our portfolio," Janssen's head of research and development William Hait said in a statement.

Genmab chief executive Jan van de Winkel said the deal would "significantly strengthen" his company's financial position, allowing it to keep developing other treatments.

The Danish company revised its full-year outlook as a result of the deal, raising its revenue forecast from the previously anticipated 375-400 million kroner (50-54 million euros, $63-67 million) to 435-460 million.

Genmab also cut its full-year operating loss forecast from 200-250 million kroner to 140-190 million.

add to favorites email to friend print save as pdf

Related Stories

Merck pays J&J $500mn in drug row settlement

Apr 15, 2011

Merck said Friday it has agreed to pay fellow US pharmaceutical giant Johnson & Johnson $500 million to end a two-year tussle over profit-sharing deals for two anti-inflammatory drugs.

Diabetes drugs helps boost Novo Nordisk in Q2

Aug 09, 2012

(AP) — Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 29 percent in the second quarter of 2012, chiefly spurred by strong sales of its new diabetes drugs.

Wind turbine maker's shares plunge 19%

Jan 04, 2012

Vestas, the world leader in the wind turbine industry, saw its share price plummet around 19 percent at the opening Wednesday, a day after issuing a profit warning.

Wind turbine maker's shares tumble on profit alert

Oct 31, 2011

Shares in Danish company Vestas, the world leader in the wind turbine industry, plunged by 20 percent on Monday after the company issued a full-year profit warning over delays on several projects.

Recommended for you

New approach to particle therapy dosimetry

Dec 19, 2014

Researchers at the National Physical Laboratory (NPL), in collaboration with EMRP partners, are working towards a universal approach to particle beam therapy dosimetry.

Supplement maker admits lying about ingredients

Dec 17, 2014

Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.